Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Osiris Therapeutics, Inc.    OSIR

Delayed Quote. Delayed  - 07/29 10:00:00 pm
5 USD   +0.81%
06/06 INVESTIGATION F : OSIR) over Potential Wrongdoing by Certain Directo..
06/02 Khang & Khang LLP Announces an Investigation of Claims against Os..
06/01 Levi & Korsinsky, LLP Announces the Commencement of an Investigat..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/25/2016 07/26/2016 07/27/2016 07/28/2016 07/29/2016 Date
5.01(c) 4.98(c) 5.02(c) 4.96(c) 5 Last
38 529 31 554 39 394 43 058 41 367 Volume
-2.34% -0.60% +0.80% -1.20% +0.81% Change
More quotes
Financials ($)
Sales 2015 94,9 M
EBIT 2015 4,40 M
Net income 2015 2,77 M
Debt 2015 -
Yield 2015 -
Sales 2016 110 M
EBIT 2016 5,03 M
Net income 2016 4,54 M
Debt 2016 -
Yield 2016 -
P/E ratio 2015 62,00
P/E ratio 2016 39,68
Capi. / Sales2015 1,80x
Capi. / Sales2016 1,55x
Capitalization 171 M
More Financials
Company
Osiris Therapeutics, Inc. engages in stem cell research and development of pharmaceutical products.Its regenerative medicine targets dermal burns, pressure ulcers, venous leg, diabetic foot ulcers, and tissue and bone repair.The company was founded by Peter A. Friedli and James S. Burns on December... 
More about the company
Surperformance© ratings of Osiris Therapeutics, Inc.
Trading Rating : - Investor Rating :
More Ratings
Latest news on OSIRIS THERAPEUTICS, INC.
06/29 OSIRIS THERAPEUTICS : Change in Directors or Principal Officers, Financial State..
06/14 OSIRIS THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
06/10 OSIRIS THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
06/06 INVESTIGATION FOR INVESTORS IN SHARE : OSIR) over Potential Wrongdoing by Certai..
06/02 Khang & Khang LLP Announces an Investigation of Claims against Osiris Therape..
06/01 Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Pos..
06/01 Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Osiris Therapeu..
05/31 Investigation of Osiris Therapeutics, Inc. Announced by Law Offices of Howard..
05/27 OSIRIS THERAPEUTICS, INC. : Other Events (form 8-K)
05/16 OSIRIS THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continue..
More news
Sector news : Bio Therapeutic Drugs
08:26aDJMerck Revenue Rises on Cancer, Hepatitis Treatments
08:10aDJMERCK : Revenue Rises on Cancer, Hepatitis Treatments
02:56aDJSanofi Profit Down as Diabetes Drug Sales Slip
07/28DJCELGENE : Lifts Guidance as Revlimid Sales Rise -- Update
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
06/10 Osiris chief resigns for medical reasons
06/03 Mesoblast trading halt to stay in place until June 10, bad news expected
06/03 Is It Time To Invest In Stem Cell Biotechs?
05/31 Midday Gainers / Losers
05/31 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
Advertisement
Chart OSIRIS THERAPEUTICS, INC.
Duration : Period :
Osiris Therapeutics, Inc. Technical Analysis Chart | OSIR | US68827R1086 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 8,00 $
Spread / Average Target 61%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David A. Dresner President & Chief Executive Officer
Peter A. Friedli Chairman
Frank D. Czworka Chief Operating Officer
Gregory I. Law Chief Financial Officer, Secretary & Treasurer
Alla Danilkovitch Chief Scientific Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
OSIRIS THERAPEUTICS, I..-52.22%171
AMGEN, INC.5.51%128 668
GILEAD SCIENCES, INC.-19.72%108 197
CELGENE CORPORATION-7.10%86 182
REGENERON PHARMACEUTIC..-24.28%43 192
VERTEX PHARMACEUTICALS..-23.54%23 798
More Results